LOQTORZI

This brand name is authorized in United States. It is also authorized in Austria, Lithuania.

Active ingredients

The drug LOQTORZI contains one active pharmaceutical ingredient (API):

1	Toripalimab UNII 8JXN261VVA - TORIPALIMAB
	Toripalimab is a humanised IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation, cytokine production, and cytotoxic activity.
	Read more about Toripalimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOQTORZI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
LOQTORZI Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF13		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1101292
US	FDA, National Drug Code	70114-340, 83718-000